Atherosclerosis and Hyperlipidemia

Madelyn Hurwitz , Olayinka J Agboola , Abhishek Gami , et al

Read time: 24m 21s
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors

Christina Magnussen

Watch time: 2m 46s
AHA 24: The ALPACAR Trial

Steven E Nissen

Watch time: 5m 28s
AHA 24: The BROOKLYN Study

Stephen Nicholls

Watch time: 3m 44s
AHA 24: The KRAKEN Trial

Stephen Nicholls

Watch time: 3m 40s
AHA 24: New Insights from CLEAR OUTCOMES

Marc P Bonaca

Watch time: 3m 49s
AHA 24 Late-Breaking Discussion: The ZODIAC Trial

Harriette Van Spall, Kausik Ray

Watch time: 29m 32s
AHA 24: The LIBerate-OLE Trial

Dean J Kereiakes

Watch time: 6m 17s
AHA 24: The LIBerate-HeFH_OLE Study

Frederick Raal

Watch time: 3m 53s
ESC 24: Day 4 Wrap-Up with Dr Alasnag and Dr Al-Shaibi

Mirvat Alasnag, Khaled Al-Shaibi

Watch time: 15m 45s
ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD

Brian Bergmark

Watch time: 3m 40s

Evan A Stein

Watch time: 7m 18s

Heather Currie , Christine Williams

Read time: 10m

Edward T Carreras , Donna M Polk

FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano

Watch time: 2m 56s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue

Watch time: 3m 30s

Sergio Fazio

Marc Sirol

Yassir Javaid et al

Watch time: 18m 47s (4 videos)

Marc P Allard-Ratick , Pratik Sandesara , Arshed A Quyyumi , et al

Donald E Cutlip

Jiaqian Xu , Michael D Shapiro

Joost Daemen, Allen Jeremias, Ziad A Ali et al

Watch time: 55m 46s (1 video)

Kilmer S McCully

Media

Nicolas M Van Mieghem, Joost Daemen

Watch time: 1h 35m 42s (16 videos)

Joost Daemen, Allen Jeremias, Ziad A Ali et al

Watch time: 55m 46s (1 video)
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen

Watch time: 22m 4s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue

Watch time: 14m 28s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur

Watch time: 14m 20s
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue

Watch time: 3m 30s

Yassir Javaid et al

Watch time: 18m 47s (4 videos)
ACC 2022 Late-breaker Discussion: The SuperWIN Trial

Dylan L Steen, Harriette Van Spall

Watch time: 16m 57s

Media

Yassir Javaid et al

Watch time: 18m 47s (4 videos)
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors

Christina Magnussen

Watch time: 2m 46s
ESC 23: LIBerate-HeFH Study

Frederick Raal

Watch time: 4m 16s
View from the Thoraxcenter: ACC.23 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen

Watch time: 33m 36s

Nicolas M Van Mieghem, Joost Daemen

Watch time: 1h 35m 42s (16 videos)
ESC 24: Day 4 Wrap-Up with Dr Alasnag and Dr Al-Shaibi

Mirvat Alasnag, Khaled Al-Shaibi

Watch time: 15m 45s
AHA 24: New Insights from CLEAR OUTCOMES

Marc P Bonaca

Watch time: 3m 49s
AHA 24: The ALPACAR Trial

Steven E Nissen

Watch time: 5m 28s
AHA 24: The BROOKLYN Study

Stephen Nicholls

Watch time: 3m 44s
AHA 24: The KRAKEN Trial

Stephen Nicholls

Watch time: 3m 40s
AHA 24: The LIBerate-HeFH_OLE Study

Frederick Raal

Watch time: 3m 53s

Evan A Stein

Watch time: 7m 18s

Articles

Secondary Prevention of Atherosclerotic Cardiovascular Disease

Madelyn Hurwitz

,

Olayinka J Agboola

,

Abhishek Gami

,

Marlene S Williams

,

Salim S Virani

,

Garima V Sharma

,

Jaideep Patel

,

Published:

28 April 2025

Citation:

US Cardiology Review 2025;19:e11.

DOI:

https://doi.org/10.15420/usc.2024.33
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 271
  • Downloads: Downloads 24
  • Read time: 24m 21s

Current Evidence and Future Directions of PCSK9 Inhibition

Jiaqian Xu

,

Michael D Shapiro

,

Published:

16 February 2021

Citation:

US Cardiology Review 2021;15:e01.

DOI:

https://doi.org/10.15420/usc.2020.17
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 4335
  • Downloads: Downloads 165

HDL Cholesterol and Adverse Outcomes

Marc P Allard-Ratick

,

Pratik Sandesara

,

Arshed A Quyyumi

,

Laurence S Sperling

,

Published:

12 March 2019

Citation:

US Cardiology Review 2019;13(1):49–53

DOI:

https://doi.org/10.15420/usc.2019.3.2
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 5396
  • Downloads: Downloads 42
  • Citations: 9

Novel Treatments for Cardiovascular Disease

Leo Buckley

,

Ahmed Aldemerdash

,

Citation:

US Cardiology Review 2017;11(2):98–104.

DOI:

https://doi.org/10.15420/usc.2017:20:2
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 2363
  • Downloads: Downloads 11
  • Citations: 1